RT Journal Article
T1 Ceftobiprole: a clinical view.
A1 Martinez Perez-Crespo, P M
A1 Lopez Cortes, L E
K1 ceftobiprole
K1 MRSA
K1 synergy
K1 anti-biofilm
AB Ceftobiprole is a broad-spectrum, fifth-generation cephalosporin currently approved for community-acquired and non-ventilator-associated hospital-acquired pneumonia. High bactericidal and anti-biofilm activity has been exhibited in in vitro and animal models. This, together with its synergism with other antibiotics against gram-positive bacteria, makes it an ideal candidate for treatment of complex infections, such as those associated with devices or infective endocarditis. More clinical data are needed to achieve drug positioning.
PB Sociedad Espanola de Quimioterapia
YR 2021
FD 2021-09-30
LK https://hdl.handle.net/10668/27300
UL https://hdl.handle.net/10668/27300
LA en
NO Martínez Pérez-Crespo PM, López Cortés LE. Ceftobiprole: a clinical view. Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):32-34.
DS RISalud
RD Apr 8, 2025